Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

4,646 total articles

AEP Executive Sells $542,320 in Restricted Stock Units; Company Cited in Multiple Upgrades and a Major PJM Approval

AEP Executive Sells $542,320 in Restricted Stock Units; Company Cited in Multiple Upgrades and a Major PJM Approval

Phillip R. Ulrich, Executive Vice President at American Electric Power Co. Inc (AEP), disposed of 4,106 restricted stock units on February 27, 2026, for $542,320 under a Rule 10b5-1 plan. Additional common stock transactions on February 26, 2026 were reported with zero recorded value. The filings coincide with AEP shares trading close to their 52-w…

Energy Vault director Larry Paulson buys $15,726 of NRGV stock as company posts first positive adjusted EBITDA

Energy Vault director Larry Paulson buys $15,726 of NRGV stock as company posts first positive adjusted EBITDA

Energy Vault Holdings director Larry Paulson purchased 5,000 shares of the company on February 27, 2026, spending $15,726 at $3.1452 per share. The trade comes as the stock has recorded a 121% gain over the last year and a 43% rise over six months, despite a 35% decline year-to-date. The company also reported its first positive adjusted EBITDA for …

Itron Finance Executive Sells Shares to Cover RSU Taxes; Analysts Lift Targets After Strong Quarter

Itron Finance Executive Sells Shares to Cover RSU Taxes; Analysts Lift Targets After Strong Quarter

Itron Inc. CFO Joan S. Hooper sold 3,533 shares on February 26, 2026, to satisfy tax-withholding tied to a restricted stock unit vesting, reducing her direct holdings to 118,275 shares. The transaction occurred at $95.9209 per share for $338,888. Separately, Itron reported fourth-quarter 2025 results that beat analyst estimates, prompting price-tar…

First Financial Bancorp internal auditor disposes $9,036 in stock amid strong quarterly results and fresh analyst coverage

First Financial Bancorp internal auditor disposes $9,036 in stock amid strong quarterly results and fresh analyst coverage

James R. Shank, Chief Internal Auditor at First Financial Bancorp (FFBC), sold 320 shares on February 27, 2026, for $9,036. The bank reported record Q4 2025 earnings and revenue, while Brean Capital initiated coverage with a Neutral rating and a $33.00 price target. Market metrics and third-party research highlight differing views on valuation.

Boston Properties Executive Sells $328K in Stock Amid Stock Weakness; Q4 Beat, Analyst Downgrade Add Mixed Signals

Boston Properties Executive Sells $328K in Stock Amid Stock Weakness; Q4 Beat, Analyst Downgrade Add Mixed Signals

Boston Properties Executive Vice President Hilary J. Spann sold 5,495 shares on February 27, 2026, generating $327,996 at prices between $59.18 and $59.77. The transaction, disclosed on an SEC Form 4, leaves Spann with 17,832 shares. The sale occurs as BXP stock trades below recent levels and after a fourth-quarter earnings beat; a recent analyst d…

Birchtech CEO Buys $750,000 of Stock as Company Prices $15M Offering and Seeks $78M Judgment Payment

Birchtech CEO Buys $750,000 of Stock as Company Prices $15M Offering and Seeks $78M Judgment Payment

Birchtech Corp.'s chief executive acquired 312,500 shares worth $750,000 as the company concurrently priced a 6,250,000-share offering at $2.40 per share and moved to collect a $78 million judgment following the expiration of a 30-day stay of execution. The trades and corporate actions come as the stock trades near its 52-week low and shows recent …

Palvella Therapeutics Director Buys $500,000 of Stock Amid Upsized Offering and Positive Phase 3 News

Palvella Therapeutics Director Buys $500,000 of Stock Amid Upsized Offering and Positive Phase 3 News

A Palvella Therapeutics director bought $500,000 of company stock on February 27, 2026, joining a period of intense corporate activity that included an upsized public offering and a bullish analyst update tied to positive phase 3 data for the company’s QTORIN Rapamycin treatment. The transaction and recent financing highlight simultaneous insider c…

Palvella Director Acquires $300,000 in Stock Amid Company Offering

Palvella Director Acquires $300,000 in Stock Amid Company Offering

A Palvella Therapeutics director purchased $300,000 worth of company stock in connection with a recently closed underwritten offering. The transaction, disclosed on a Form 4, coincides with a large public share sale that generated $230 million in gross proceeds and an analyst upgrade following positive phase 3 data for the company’s QTORIN Rapamyci…